Solara Active Pharma to carry out internal probe on Nizatidine API amid Mylan recall

09 Jan 2020 Evaluate

Solara Active Pharma Sciences is going to carry out internal probe on Nizatidine API amid the voluntary recall of Nizatidine API by Mylan. The company is in the process of collecting corresponding lots of API from Mylan to carry out internal investigation.

Mylan N.V.'s US based Mylan Pharmaceuticals (Mylan) has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150mg and 300mg strengths) due to detected trace amounts of impurity N-nitrosodimethylamine (NDMA) contained in the Nizatidine API. Mylan also indicated that the recall is voluntary, and the company has not received any reports of adverse events related to these batches to date.

Solara Active Pharma Sciences’ last supplies of Nizatidine API to Mylan were made in September 2017.

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.

Solara Active Pharma Share Price

536.20 15.80 (3.04%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×